Home » Industry News »
NICE funding impacts treatment sequencing patterns in chronic myeloid leukaemia (CML)
NICE recommendations determine access to tyrosine kinase inhibitors (TKIs) Median duration of treatment by line also decreased as more TKIs were recommended by NICE Promisingly,…
Use of real-world evidence to create standardised treatment pathways is essential for the future of oncology
“A truly high-value drug is the one that costs the least and has the most benefit for our patients” “What we need is more research…
Baseline UK real-world study in ovarian cancer pre-PARPi published
A study was published recently on the real-world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in…
UK real-world evidence study in advanced NSCLC Less than 30% of patients treated second line
Over the past 10 years, the management of NSCLC has seen the introduction of targeted treatments, from EGFR to ALK and, more recently, PD-L1 In…
Introduction of e-prescribing in cancer improved safety 10-fold
Electronic prescribing records were introduced as they offer vastly improved communication between different healthcare professionals and patients, which was found to be the source of…
Real-world data show that filters clean COVID-causing virus from air
The results suggest that air filters could be used to reduce the risk of patients and medical staff contracting SARS-CoV-2 in hospitals, the study’s authors…
RWE helps accelerate oncology drug development timelines by 1-3 years
Key insights from the research included: engage the FDA early to confirm appropriate data sources; select appropriate data sources to ensure real-world data are high…
Emulating control arms for oncology clinical trials using real-world data
Trial data was used from published control arm results from 15 trials that supported drug approvals from January 1, 2016, to April 30, 2018 RWD…
NHS has uniquely beneficial healthcare data and real-world evidence to improve oncology outcomes
Real-world evidence generated by the NHS has a broad range of applications in research that can inform regulatory filings by assessing safety and effectiveness, and…
Cabometyx (cabozantinib) demonstrates real-world survival benefit in advanced renal cell carcinoma
The study analysed outcomes of adults who were diagnosed with stage III or IV RCC between January 1, 2011 and December 31, 2018, with follow-up…